

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1003R1C1D1	Serial No. To Be Assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Akita et al.	
				Filing Date 04 Apr 2001	Group To Be Assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
CY	*25	Kraus et al., "Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors" <u>Proc. Natl. Acad. Sci. USA</u> 86:9193-9197 (Dec 1989)			
CY	*26	Lee et al., "Assignment of heregulin (HGL) to human chromosome 8p22-p11 by PCR analysis of somatic cell hybrid DNA" <u>Genomics</u> 16:790-791 (1993)			
CY	*27	Lemoine et al., "Expression of the ERBB3 gene product in breast cancer" <u>Br. J. Cancer</u> 66:1116-1121 (1992)			
CY	*28	Lemoine et al., "The erbB-3 gene in human pancreatic cancer" <u>J. Pathol.</u> 168:269-273 (1992)			
CY	*29	Levi et al., "The Influence of Heregulins on Human Schwann Cell Proliferation" <u>J. Neuroscience</u> 15(2):1329-1340 (Feb 1995)			
CY	*30	Lewis et al., "Growth Regulation of Human Breast and Ovarian Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in Mediating Heregulin Responsiveness" <u>Cancer Research</u> 56:1457-1465 (Mar 15, 1996)			
CY	*31	Marchionni et al., "Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system" <u>Nature</u> 362:312-318 (1993)			
CY	*32	Morrissey et al., "Axon-induced mitogenesis of human Schwann cells involves heregulin and p185erbB2" <u>Proc. Natl. Acad. Sci. USA</u> 92:1431-1435 (Feb 1995)			
CY	*33	Orr-Utreger et al., "Neural expression and chromosomal mapping of Neu differentiation factor to 8p12-p21" <u>Proc. Natl. Acad. Sci. USA</u> 90:1867-1871 (1993)			
CY	*34	Peles et al., "Isolation of the Neu/HER-2 Stimulatory Ligand: A 44 Kd Glycoprotein That Induces Differentiation of Mammary Tumor Cells" <u>Cell</u> 69(1):205-216 (1992)			
CY	*35	Plowman et al., "Heregulin induces tyrosine phosphorylation of HER4/p180erbB4" <u>Nature</u> (Letters to Nature) 366:473-475 (Dec 2, 1993)			
CY	*36	Plowman et al., "Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family" <u>Proc. Natl. Acad. Sci. USA</u> 90:1746-1750 (Mar 1993)			
CY	*37	Plowman et al., "Molecular cloning and expression of an additional epidermal growth factor receptor-related gene" <u>Proc. Natl. Acad. Sci.</u> 87:4905-4909 (1990)			
CY	*38	Poller et al., "Production and characterization of a polyclonal antibody to the c-erbB-3 protein: examination of c-erbB-3 protein expression in adenocarcinomas" <u>J. Pathol.</u> 168(3):275-280 (1992)			
CY	*39	Rajkumar et al., "A monoclonal antibody to the human c-erbB3 protein stimulates the anchorage-independent growth of breast cancer cell lines" <u>Br. J. Cancer</u> 70(3):459-465 (1994)			
CY	*40	Rajkumar et al., "Expression of the c-erbB-3 protein in gastrointestinal tract tumours determined by monoclonal antibody RTJ1" <u>J. Pathol.</u> (Published erratum appears in J. Pathol. 1993 Oct;171(2):154) 170:271-278 (1993)			
CY	*41	Ram et al., "Mitogenic Activity of Neu Differentiation Factor/Heregulin Mimics That of Epidermal Growth Factor and Insulin-Like Growth Factor-1 in Human Mammary Epithelial Cells" <u>J. Cellular Physiology</u> 163:589-596 (1995)			
CY	*42	Sanidas et al., "Expression of the c-erbB-3 gene product in gastric cancer" <u>Int. J. Cancer</u> 54:935-940 (1993)			
CY	*43	Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" <u>Science</u> 235:177-182 (Jan 9, 1987)			
CY	*44	Slamon et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer" <u>Science</u> 244:707-712 (May 12, 1989)			
Examiner <i>Christopher H Yan</i>			Date Considered <i>10.10.02</i>		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1003R1C1D1Serial No.
09/825,584
To Be Assigned

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Akita et al.Filing Date
04 Apr 2001
Group 1642
To Be Assigned

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
CY	* 1	4,975,278	04.12.90	Senter et al.			
CY	* 2	5,183,884	02.02.93	Kraus et al.			
CY	* 3	5,480,968	02.01.96	Kraus et al.			
CY	4	5,968,511	19.10.99	Akita et al.			

929 U.S. PTO
09/825,584
04/04/01

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Yes	No
CY	* 5	0,599,274 A1	01.06.94	EPO				
CY	* 6	444,961	04.09.91	EPO				
CY	* 7	502,812	09.09.92	EPO				
CY	* 8	WO 91/08214	13.06.91	PCT				
CY	* 9	WO 92/20798	26.11.92	PCT				
CY	* 10	WO 93/16185	19.08.93	PCT				
CY	* 11	WO 93/21319	28.10.93	PCT				
CY	* 12	WO 94/04679	03.03.94	PCT				
CY	* 13	WO 94/08007	14.04.94	PCT				
CY	* 14	WO 94/22478	13.10.94	PCT				
CY	* 15	WO 95/14776	01.06.95	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

CY	*16	Bacus et al., "Expression of the erbB-2 Family of Growth Factor Receptors and Their Ligands in Breast Cancers" <u>Pathology Patterns</u> (Suppl.1) 102(4):S13-S24 (1994)
CY	*17	Falls et al., "ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the Neu ligand family" <u>Cell</u> 72:801-815 (1993)
CY	*18	Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product" <u>Cancer Research</u> 50:1550-1558 (Mar 1, 1990)
CY	*19	Friess et al., "Enhanced erbB-3 Expression in Human Pancreatic Cancer Correlates with Tumor Progression" <u>Clinical Cancer Research</u> 1:1413-1420 (1995)
CY	*20	Griffiths et al., "Human Anti-Self Antibodies With High Specific From Phage Display Libraries" <u>EMBO Journal</u> 12(2):725-734 (1993)
CY	*21	Guy et al., "Insect Cell-expressed p180erbB3 Possesses an Impaired Tyrosine Kinase Activity" <u>Proc. Natl. Acad. Sci. USA</u> 91:8132-8136 (August 1994)
CY	*22	Holmes et al., "Identification of Heregulin, a Specific Activator of p185erbB2" <u>Science</u> 256:1205-1210 (May 22, 1992)
CY	*23	Kim et al., "Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product" <u>Journal of Biological Chemistry</u> 269(40):24747-24755 (1994)
CY	*24	Kraus et al., "Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells" <u>Proc. Natl. Acad. Sci.</u> 90:2900-2904 (1993)

Examiner

Chrysoph H. Yen

Date Considered

10.10.02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORIV PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1003R1C1D1	Serial No. To Be Assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Akita et al.		
		Filing Date 04 Apr 2001	Group To Be Assigned	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
CY	*45	Sliwkowski et al., "Coexpression of erbB2 and erbB3 Proteins Reconstitutes a High Affinity Receptor for Heregulin" <u>Journal of Biological Chemistry</u> 269(20):14661-14665 (May 20, 1994)		
CY	*46	Wallasch et al., "Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3" <u>EMBO Journal</u> 14(17):4267-4275 (1995)		
CY	*47	Wen et al., "Neu differentiation factor: a transmembrane glycoprotein containing an EGF Domain and an Immunoglobulin Homology Unit" <u>Cell</u> 69(3):559-572 (1992)		
CY	*48	Wen et al., "Structural and functional aspects of the multiplicity of neu differentiation factors" <u>Molecular & Cellular Biology</u> 14(3):1909-1919 (1994)		
Examiner	<i>Chris Loh Wei Yu</i>		Date Considered	10.10.02
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449				U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1003R1C1D1	Serial No. 09/825, 584
				Applicant Akita et al.		
				Filing Date 04 Apr 2001	Group 1645	1642
FOREIGN PATENT DOCUMENTS						



Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
CY	49	WO 97/20858	12.06.97	PCT			

RECEIVED
MAY 10 2002
TECH CENTER 1600/2900

Examiner <i>Christoph H. Yen</i>	Date Considered <i>10.10.02</i>
-------------------------------------	------------------------------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

• FORM PTO-1449.

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1003R1C1D1Serial No.
09/825,584

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

AUG 12 2002

Applicant
Akita et al.Filing Date
04 Apr 2001Group
1642

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
CY	50	5,783,186	21.07.98	Arakawa et al.			
CY	51	5,783,404	21.07.98	Koski, R.			

Examiner	Christoph H Yen	Date Considered
----------	-----------------	-----------------

10.17.02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.